


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


Claim 1 (original): A compound of the formula I:




I

or a pharmaceutically acceptable salt, hydrate, solvate or mixture thereof, wherein:


- (a) each occurrence of m is independently an integer ranging from 0 to 5;
- (b) each occurrence of n is independently an integer ranging from 3 to 7;
- (c) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;
- (d) each occurrence of R^1 , R^2 , R^{11} , and R^{12} is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl, wherein R^1 , R^2 , R^{11} , and R^{12} are not each simultaneously H; and
- (e) each occurrence of Y^1 and Y^2 is independently (C_1-C_6) alkyl, OH, COOH, COOR³, SO₃H,





wherein:

- (i) Y^1 and Y^2 are not each simultaneously (C_1-C_6) alkyl;
- (ii) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (iii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iv) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl.



wherein:

- (i) Y^1 and Y^2 are not each simultaneously (C_1-C_6) alkyl;
- (ii) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (iii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups; and
- (iv) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl.

Claim 2 (original): The compound of claim 1, wherein each occurrence of Y^1 and Y^2 is independently OH, $COOR^3$, or COOH.

Claim 3 (original): The compound of claim 1, wherein m is 0.

Claim 4 (original): The compound of claim 1, wherein m is 1.

Claim 5 (original): The compound of claim 1, wherein n is 4.

Claim 6 (original): The compound of claim 1, wherein n is 5.

Claim 7 (original): The compound of claim 1, wherein z is 0.


Claim 8 (original): The compound of claim 1, wherein z is 1.

Claim 9 (original): The compound of claim 1, wherein Y^1 is (C_1-C_6) alkyl and Y^2 is OH.

Claim 10 (original): The compound of claim 1, wherein Y^1 is methyl and Y^2 is OH.

Claims 11 – 27 (canceled).


Claim 28 (withdrawn): A compound of the formula **III**




or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein

- (a) each occurrence of R^1 , R^2 , R^6 , R^7 , R^{11} , or R^{12} is independently hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;

- (b) each occurrence of n is independently an integer ranging from 1 to 7;
- (c) X is $(\text{CH}_2)_z$ or Ph, wherein z is an integer from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;
- (d) each occurrence of m is independently an integer ranging from 0 to 4;
- (e) each occurrence of Y^1 and Y^2 is independently $(\text{C}_1\text{--}\text{C}_6)\text{alkyl}$, CH_2OH , $\text{C}(\text{O})\text{OH}$, $\text{OC}(\text{O})\text{R}^3$, $\text{C}(\text{O})\text{OR}^3$, SO_3H ,






wherein:


- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
 - (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups;
 - (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- (f) b is 0 or 1 and optionally the ring contains the presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds such that when b is 0 the maximum number of carbon-carbon bonds is two or when b is 1 the maximum number of carbon-carbon bonds is three.


Claim 29 (withdrawn): A compound of the formula IV:



or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein

- (a) each occurrence of R^1 , R^2 , R^6 , R^7 , R^{11} , or R^{12} is independently hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (b) each occurrence of n is independently an integer ranging from 1 to 7;
- (c) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;
- (d) each occurrence of m is independently an integer ranging from 0 to 4;
- (e) each occurrence of Y^1 and Y^2 is independently (C_1-C_6) alkyl, CH_2OH , $C(O)OH$, $OC(O)R^3$, $C(O)OR^3$, SO_3H ,






wherein:



- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups;
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- (f) each occurrence of b is independently 0 or 1 and optionally each of the rings independently contains the presence of one or more additional carbon-carbon bonds that when present complete one or more carbon-carbon double bonds such that when b is 0 the maximum number of carbon-carbon bonds is two or when b is 1 the maximum number of carbon-carbon bonds is three.


Claim 30 (withdrawn): A compound of the formula V:



or a pharmaceutically acceptable salt, hydrate, solvate, or mixtures thereof, wherein

- (a) each occurrence of R¹, R², R⁶, R⁷, R¹¹, or R¹² is independently hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benyl;
- (b) each occurrence of n is independently an integer ranging from 1 to 7;
- (c) X is (CH₂)_z or Ph, wherein z is an integer from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;
- (d) each occurrence of m is independently an integer ranging from 0 to 4;
- (e) each occurrence of Y¹ and Y² is independently (C₁-C₆)alkyl, CH₂OH, C(O)OH, OC(O)R³, C(O)OR³, SO₃H,






wherein:

- (i) R^3 is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^4 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, C_1-C_6 alkoxy, or phenyl groups;
- (iii) each occurrence of R^5 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl; and
- (f) b is 0 or 1 and optionally the ring contains one or more carbon-carbon bonds that when present complete one or more carbon-carbon double bonds.



Claim 31 (withdrawn): A compound of the formula **VI**:




VI

or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein:

- (a) each occurrence of R^1 , R^2 , R^6 , R^7 , R^{11} , or R^{12} is independently hydrogen, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl;
- (b) each occurrence of n is independently an integer ranging from 1 to 7;
- (c) X is $(CH_2)_z$ or Ph, wherein z is an integer from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;
- (d) each occurrence of m is independently an integer ranging from 0 to 4;
- (e) each occurrence of Y^1 and Y^2 is independently (C_1-C_6) alkyl, CH_2OH , $C(O)OH$, $OC(O)R^3$, $C(O)OR^3$, SO_3H ,






wherein:

- (i) R³ is (C₁–C₆)alkyl, (C₂–C₆)alkenyl, (C₂–C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁–C₆)alkoxy, or phenyl groups,
- (ii) each occurrence of R⁴ is independently H, (C₁–C₆)alkyl, (C₂–C₆)alkenyl, or (C₂–C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, C₁–C₆ alkoxy, or phenyl groups; and

Claim 32 (withdrawn):


A compound of the formula **VII**:




VII

or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein

- (a) Z is CH₂, CH=CH, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then its associated m is 1;
- (b) G is (CH₂)_x, where x is 1, 2, 3, or 4, CH₂CH=CHCH₂, CH=CH, CH₂-phenyl-CH₂, or phenyl;
- (c) each occurrence of Y¹ and Y² is independently L, V, C(R¹)(R²)-(CH₂)_c-C(R³)(R⁴)-(CH₂)_n-Y, or C(R¹)(R²)-(CH₂)_c-V where c is 1 or 2 and n is an integer ranging from 0 to 4; when G is (CH₂)_x, where x is 1, 2, 3, or 4, W² is CH₃;
- (d) each occurrence of R¹ or R² is independently (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl or when one or both of Y¹ and Y² is C(R¹)(R²)-(CH₂)_c-C(R³)(R⁴)-(CH₂)_n-W, then R¹ and R² can both be H to form a methylene group;
- (e) R³ is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)alkoxy, phenyl, benzyl, Cl, Br, CN, NO₂, or CF₃;
- (f) R⁴ is OH, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)alkoxy, phenyl, benzyl, Cl, Br, CN, NO₂, or CF₃;
- (g) L is C(R¹)(R²)-(CH₂)_n-W;
- (h) V is:




- (i) each occurrence of W is independently OH, COOH, CHO, COOR⁵, SO₃H,



wherein:

- (i) R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,
 - (ii) each occurrence of R⁶ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, (C₁-C₆) alkoxy, or phenyl groups;
 - (iii) each occurrence of R⁷ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl; and
- (j) X is (CH₂)_z or Ph, wherein z is an integer from 0 to 4.

Claim 33 (withdrawn): A compound of the formula **VIII**:



VIII


or a pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein

- (a) each occurrence of Z is independently CH₂, CH=CH, or phenyl where each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then m is 1;
- (b) G is (CH₂)_x, CH₂CH=CHCH₂, CH=CH, CH₂-phenyl-CH₂, or phenyl, where x is 1 to 7;
- (c) W¹ and W² are independently L, V, G, C(R¹)(R²)-(CH₂)_c-C(R³)(R⁴)-(CH₂)_n-Y, or C(R¹)(R²)-(CH₂)_c-V where c is 1 or 2 and n is an integer ranging from 0 to 7; when G is (CH₂)_x, where x is 1, 2, 3, or 4, W¹ is CH₃;
- (d) each occurrence of R¹ or R² is independently -H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl or when one or both of W¹ and W² is C(R¹)(R²)-(CH₂)_c-C(R³)(R⁴)-(CH₂)_n-Y, then R¹ and R² can both be H to form a methylene group;
- (e) R³ is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)alkoxy, phenyl, benzyl, Cl, Br, CN, NO₂, or CF₃;
- (f) R⁴ is H, OH, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)alkoxy, phenyl, benzyl, Cl, Br, CN, NO₂, or CF₃;

wherein:

- (i) R^5 is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C_1-C_6) alkoxy, or phenyl groups,
- (ii) each occurrence of R^6 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl and is unsubstituted or substituted with one or two halo, OH, (C_1-C_6) alkoxy, or phenyl groups; and
- (iii) each occurrence of R^7 is independently H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, or (C_2-C_6) alkynyl.

Claim 34 (withdrawn): A compound of the formula IX:




IX


or pharmaceutically acceptable salt, hydrate, solvate, or mixture thereof, wherein


- (a) each occurrence of Z is independently CH_2 , $CH-CH$, or phenyl, where each occurrence of m is independently an integer ranging from 1 to 9, but when Z is phenyl then its associated m is 1;
- (b) G is $(CH_2)_x$, where x is 1 to 7, $CH_2CH=CHCH_2$, $CH=CH$, CH_2 -phenyl- CH_2 , or phenyl;
- (c) W^1 and W^2 are independently L, V, $C(R^1)(R^2)-(CH_2)_c-C$, or $C(R^3)(R^4)-(CH_2)_n-Y$ or $C(R^1)(R^2)-(CH_2)_c-V$ where c is 1 or 2 and n is an integer from 0 to 4; when G is $(CH_2)_x$, where x is 1 to 7, W^2 is CH_3 ;
- (d) each occurrence of R^1 or R^2 is independently (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, phenyl, or benzyl, and R^1 and R^2 can both be H when one or both of W^1 and W^2 is $C(R^3)(R^4)-(CH_2)_n-Y$;

- (e) R^3 is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (f) R^4 is OH, (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkoxy, phenyl, benzyl, Cl, Br, CN, NO_2 , or CF_3 ;
- (g) L is $C(R^1)(R^2)-\{CH_2\}_n-Y$;
- (h) V is:



- (i) each occurrence of Y^1 and Y^2 is independently OH, COOH, CHO, $COOR^5$, SO_3H ,







wherein:

- (i) R⁵ is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C₁-C₆)alkoxy, or phenyl groups,
- (ii) each occurrence of R⁶ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl and is unsubstituted or substituted with one or two halo, OH, (C₁-C₆)alkoxy, or phenyl groups; and
- (iii) each occurrence of R⁷ is independently H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, or (C₂-C₆)alkynyl.


Claim 35 (currently amended): A compound of structure:




2,2,14,14-Tetramethyl-pentadecane-1,8,15-triol;



8-Hydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid;



2,2,12,12-Tetramethyl-tridecane-1,7,13-triol;



7-Hydroxy-2,2,12,12-tetramethyl-tridecanedioic acid;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 36 (currently amended): A pharmaceutical composition comprising a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65 and a pharmaceutically acceptable vehicle, excipient, or diluent.

Claim 37 (currently amended): A pharmaceutical composition comprising a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65 and further comprising a second therapeutic agent.

Claim 38 (currently amended): A method for treating or preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder, modulating C reactive protein, or enhancing bile production in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 39 (currently amended): A method for treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 40 (currently amended): A method for treating or preventing a dyslipidemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically, ~~or prophylactically~~ effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 41 (currently amended): A method for treating or preventing a dyslipoproteinemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 42 (currently amended): A method for treating or preventing a disorder of glucose metabolism in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 43 (currently amended): A method for treating or preventing Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 44 (currently amended): A method for treating or preventing Syndrome X in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 45 (currently amended): A method for treating or preventing a septicemia in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35, 62, 63, 64, or 65.~~

Claim 46 (currently amended): A method for treating or preventing a thrombotic disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35, 62, 63, 64, or 65.~~

Claim 47 (currently amended): A method for treating or preventing a peroxisome proliferator activated receptor associated disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35, 62, 63, 64, or 65.~~

Claim 48 (currently amended): A method for treating or preventing obesity in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35, 62, 63, 64, or 65.~~

Claim 49 (currently amended): A method for treating or preventing pancreatitis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35, 62, 63, 64, or 65.~~

Claim 50 (currently amended): A method for treating or preventing hypertension in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35, 62, 63, 64, or 65.~~

Claim 51 (currently amended): A method for treating or preventing renal disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 52 (currently amended): A method for treating or preventing cancer in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 53 (currently amended): A method for treating or preventing inflammation in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 54 (currently amended): A method for treating or preventing impotence in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 55 (currently amended): A method for treating or preventing a neurodegenerative disease or disorder in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 56 (currently amended): A method of inhibiting hepatic fatty acid synthesis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35~~, 62, 63, 64, or 65.

Claim 57 (currently amended): A method of inhibiting sterol synthesis in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35,~~ 62, 63, 64, or 65.


Claim 58 (currently amended): A method of treating or preventing metabolic syndrome disorders in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35,~~ 62, 63, 64, or 65.

Claim 59 (currently amended): A method of treating or preventing a disease or disorder that is capable of being treated by increasing HDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35,~~ 62, 63, 64, or 65.

Claim 60 (currently amended): A method of treating or preventing a disease or disorder that is capable of being treated by lowering LDL levels, which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35,~~ 62, 63, 64, or 65.

Claim 61 (currently amended): A pharmaceutical composition comprising a compound of claim 1, ~~11, 28, 29, 30, 31, 32, 33, 34, or 35,~~ 62, 63, 64, or 65 and a pharmaceutically acceptable vehicle, excipient, or diluent which is administered in combination with a statin.


Claim 62 (new): A compound according to claim 1 wherein said compound has the structure:



2,2,14,14-Tetramethyl-pentadecane-1,8,15-triol;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.


Claim 63 (new): A compound according to claim 1 wherein said compound has the structure:



8-Hydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.


Claim 64 (new): A compound according to claim 1 wherein said compound has the structure:



2,2,12,12-Tetramethyl-tridecane-1,7,13-triol;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 65 (new): A compound according to claim 1 wherein said compound has the structure:



7-Hydroxy-2,2,12,12-tetramethyl-tridecanedioic acid; ;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.